*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. While the Italian competition authority has made very few forays into the area of excessive pricing, recent decisional practice shows a renewed interest in this type of practice assessed from the perspective of exclusionary or exploitative practices (for a recent example in the pharmaceutical sector see F. Marini Balestra, L. Antonazzi, "The Italian Supreme Administrative Court rejects an appeal lodged by a multinational drug company against a previous decision asserting it as having abused its dominant position by imposing unfair prices for drugs (Aspen)", e-Competitions March 2020, Art. n° 95455). In this case, following a complaint filed in 2018 in
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.